Nu.Q® Cancer

An epigenetic solution to help detect, guide treatment, and monitor cancer.

Our Nu.Q^® technology

Cancer

Cancer is a devastating disease that touches many peoples’ lives, accounting for approximately 10 million deaths worldwide each year.

Overview

Cancer is the second leading cause of death globally and exerts an enormous burden on families, communities, and health systems. Survival rates are improving in countries with strong health systems, thanks to advances in cancer detection and treatment. However, access to timely diagnostics and therapies remains limited for cancer patients in low and middle-income countries.

0 m

Cancer cases worldwide

0 m

Lung Cancer cases

0 k

Ovarian Cancer cases

0 k

Non-Hodgkin Lymphoma cases

Our Solution

We are developing Nu.Q^® Cancer – a range of simple, cost-effective blood-based assays.

Our patented Nucleosomics™ technology isolates circulating nucleosomes from the blood for quantiﬁcation and analysis.

Nu.Q^® can detect characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer and has potential applications beyond cancer detection. Being able to use epigenetic information from the nucleosomes of tumor cells could help physicians:

Predict treatment response for each patient.
Monitor treatment response and disease progression.
Amend a patient’s cancer treatment regimen as quickly as possible.

Nu.Q^® Cancer could also play a pivotal role in Minimal Residual Disease monitoring.

Download our Nu.Q^® Cancer Test Brochure

Nu.Q^® Cancer

Focus areas.

We are currently investigating the potential use of Nu.Q^® tests in a range of cancers and clinical settings.

Disease and treatment monitoring

Nu.Q^® Cancer can be used at diagnosis to measure and monitor nucleosome levels and modifications in circulating blood. It provides a baseline for oncologists and may enable them to predict how effective a treatment will be for a patient. They could also use our test throughout treatment to track a patient’s disease progression – potentially making timely, vital changes to their treatment regimen to ensure the best outcome.

Lung Cancer

Ovarian Cancer

Non-Hodgkin Lymphoma

Minimal Residual Disease Monitoring

Nu.Q^® Cancer could also play a pivotal role in Minimal Residual Disease Monitoring – to quantify and monitor the small number of cancer cells left in the body after cancer treatment, which have the potential to cause relapse.

Our simple, routine blood test could help catch signs of the disease coming back early, guide decision-making and an oncologist’s next steps.

Lung Cancer

Ovarian Cancer

Non-Hodgkin Lymphoma

Collaboration

Working together.

We are working with teams at clinical centers of excellence worldwide, as they undertake studies to test our technology as an aid for cancer detection, disease progression and treatment response monitoring.

About

OncoProLung is a study undertaken with Hospices Civils de Lyon in France, led by Prof. Lea Payen

Study Overview

Retrospective analysis of 70 lung cancer patients with multiple timepoints to assess the potential value of Nu.Q^® assays at diagnosis, during treatment and at relapse.

Next steps

Results due Q2 2024.

RHU REVEAL is being undertaken by Institut Gustave Roussy in France, a leading European cancer center, and focuses on non-small cell lung cancer.

Study Overview

Large scale, retrospective and prospective studies to assess the potential value of Nu.Q^® assays in combination with other blood-based mutation agnostics tests to detect Minimal Residual Disease post-primary treatment, to predict treatment response, and to monitor treatment response.

Next steps

Results due for Retrospective Analysis in 2024 and Prospective Analysis in 2026.

About

Taking part in “ILYAD” (Lyonnaise Initiative for the Initiation of Lung Cancer Screening) with Hospices Civils de Lyon in France, led by Pr. Sébastien Couraud

Study Overview

Large lung cancer screening study (with over 400 subjects) to assess the potential value of Nu.Q^® assays in the detection of cancers in screened individuals.

Next steps

Results due Q4 2024

Collaboration with Dr. Pei-Hsing Chen from National Taiwan University Hospital, focusing on lung cancer.

Study Overview

Large validation study to assess the potential value of Nu.Q^® assays in differentiating lung cancer and non-malignant nodules, for use as a complementary biomarker alongside Low Dose CT and help reduce its false positive rate.

Next steps

The study is part of a longer-term research collaboration with National Taiwan University Hospital.

About

Ovarian cancer study undertaken with Hospice Civils de Lyon in France, led by Dr Benoit You.

Study Overview

Retrospective study to assess the potential value of Nu.Q^® assays in the detection and prognosis of ovarian cancer.

Next steps

Results to be presented at ESGO in March 2024.

About

Non-Hodgkin Lymphoma study being led by Dr Christophe Marzac at the Institut Gustave Roussy in France, a leading European cancer center.

Study Overview

Prospective longitudinal study to assess the potential value of using Nu.Q^® assays to measure circulating nucleosomes in patients receiving first-line treatment for Non-Hodgkin Lymphoma.

Next steps

To finalize prospective sample collection at each treatment cycle. Results due 2025.

Find out more

Download our brochure for more details about the potential predictive, diagnostic, and prognostic value of Nu.Q^® Cancer in clinical settings.

Download our brochure

Product Resources

Brochure & Clinical Papers

An epigenetic solution to help detect, guide treatment, and monitor cancer.

Cancer is a devastating disease that touches many peoples’ lives, accounting for approximately 10 million deaths worldwide each year.

Overview

We are developing Nu.Q^® Cancer – a range of simple, cost-effective blood-based assays.

Our patented Nucleosomics™ technology isolates circulating nucleosomes from the blood for quantiﬁcation and analysis.

Nu.Q^® Cancer could also play a pivotal role in Minimal Residual Disease monitoring.

Focus areas.

We are currently investigating the potential use of Nu.Q^® tests in a range of cancers and clinical settings.

Disease and treatment monitoring

Lung Cancer

Ovarian Cancer

Non-Hodgkin Lymphoma

Minimal Residual Disease Monitoring

Lung Cancer

Ovarian Cancer

Non-Hodgkin Lymphoma

Working together.

Find out more

Brochure & Clinical Papers

Nu.Q^® Cancer Brochure

Baseline values of circulating nucleosomes in Lung Cancer: N…

Improve Molecular Residual Disease monitoring by combining c…

Circulating H3K27 methylated nucleosome concentration in lun…

Circulating H3K27 nucleosomes to monitor lung cancer patient…

Volition to Participate in a Lung Cancer Screening Study in …

Circulating H3K27 Methylated Nucleosome Plasma Concentration

Epigenetic profiles of elevated cell free circulating H3.1 n…

EZH2 inhibition: a promising strategy to prevent cancer immu…

Contact Nu.Q^® Cancer Team

Modal Contact Form (Cancer)

An epigenetic solution to help detect, guide treatment, and monitor cancer.

Cancer is a devastating disease that touches many peoples’ lives, accounting for approximately 10 million deaths worldwide each year.

Overview

We are developing Nu.Q® Cancer – a range of simple, cost-effective blood-based assays.

Our patented Nucleosomics™ technology isolates circulating nucleosomes from the blood for quantiﬁcation and analysis.

Nu.Q® Cancer could also play a pivotal role in Minimal Residual Disease monitoring.

Focus areas.

We are currently investigating the potential use of Nu.Q® tests in a range of cancers and clinical settings.

Disease and treatment monitoring

Lung Cancer

Ovarian Cancer

Non-Hodgkin Lymphoma

Minimal Residual Disease Monitoring

Lung Cancer

Ovarian Cancer

Non-Hodgkin Lymphoma

Working together.

Find out more

Brochure & Clinical Papers

Nu.Q® Cancer Brochure

Baseline values of circulating nucleosomes in Lung Cancer: N…

Improve Molecular Residual Disease monitoring by combining c…

Circulating H3K27 methylated nucleosome concentration in lun…

Circulating H3K27 nucleosomes to monitor lung cancer patient…

Volition to Participate in a Lung Cancer Screening Study in …

Circulating H3K27 Methylated Nucleosome Plasma Concentration

Epigenetic profiles of elevated cell free circulating H3.1 n…

EZH2 inhibition: a promising strategy to prevent cancer immu…

We are developing Nu.Q^® Cancer – a range of simple, cost-effective blood-based assays.

Nu.Q^® Cancer could also play a pivotal role in Minimal Residual Disease monitoring.

We are currently investigating the potential use of Nu.Q^® tests in a range of cancers and clinical settings.

Nu.Q^® Cancer Brochure